Inhibition of DNA methylation in malignant MOLT F4 lymphoblasts by 6- mercaptopurine

Clinical Chemistry

Volumn 44, Issue 3, 1998, Pages 556-559

  Lambooy, Lambert H J ^a   Leegwater, Peter A J ^a   Van Den Heuvel, Lambert P ^a   Bökkerink, Jos P ^a   De Abreu, Ronney A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBON 14; MERCAPTOPURINE; RIBONUCLEASE; TRITIUM;

ARTICLE; DNA DETERMINATION; DNA METHYLATION; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ISOTOPE LABELING; LYMPHOBLAST; PHOSPHATE METABOLISM;

TRITIUM;

EID: 0031889458     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.3.556     Document Type: Article

References (17)

1. Maurer AM. Therapy of acute lymphoblastic leukemia in childhood. Blood 1980;56:1-10.
2. McCormack JJ, Johns DG. Purine antimetabolites. In: Chabner BA, ed. Pharmacologic principles of cancer treatment. Philadelphia: Saunders, 1982:213-27.
3. Lukens LN, Herrington KA. Enzymatic formation of 6-mercaptopurine riboside. Biochem Pharmacol 1957;24:432-3.
4. Brockman RW, Bennett LL Jr, Simpson MS, Wilson AR, Thomson JR, Skipper HE. Mechanism of resistance to 8-azaguanine II. Studies with experimental neoplasms. Cancer Res 1959;19:856-69.
5. Maybaum J, Handel HG. Differential chromatid damage induced by 6-thioguanine in CHO cells. Exp Cell Res 1981;135:465-8.
6. Pan BF, Nelson JA. Characterization of the DNA damage in 6-thioguanine treated cells. Biochem Pharmacol 1990;40: 1063-9.
7. Vogt MHJ, Stet EH, De Abreu RA, Bökkerink JPM, Lambooy LHJ, Trijbels JMF. The importance of methylthio-IMP for 6-methylmercaptopurine ribonucleoside (MeMPR) cytotoxicity in MOLT F4 human malignant T-lymphoblasts. Biochim Biophys Acta 1993; 1181:189-94.
8. Stet EH, De Abreu RA, Bökkerink JPM, Lambooy LHJ, Vogels-Mentink TM, Keizer-Garritsen JJ, Trijbels JMF. Reversal of 6-mercaptopurine (6MP) and 6-methylmercaptopurine ribonucleoside (MeMPR) cytotoxicity by amidoimidazole carboxamide ribonucleoside (AICAR) in MOLT F4 human malignant T-lymphoblasts. Biochem Pharmacol 1995;49:49-56.
9. Stet EH, De Abreu RA, Bökkerink JP, Blom HJ, Lambooy LH, Vogels-Mentink TM, et al. Decrease in S-adenosyl-methionine synthesis by 6-mercaptopurine and methyl mercaptopurine ribonucleoside in MOLT F4 human malignant lymphoblasts. Biochem J 1994;304(Pt 1):163-8.
10. De Abreu R, Lambooy L, Stet E, Vogels-Mentink T, Van den Heuvel L. Thiopurine induced disturbance of DNA methylation in human malignant cells. Enzym Regulation 1995;35:251-63.
11. Blow JJ. Methyltransferases in foci. Nature 1993;361:684-5.
12. Lennard L, Lilleyman JS, Maddocks JL. The effect of folate supplements on 6-mercaptopurine remission maintenance therapy in childhood leukemia. Br J Cancer 1986;53:115-9.
13. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
14. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
15. Gehrke CW, McCune RA, Gama-Sosa MA, Ehrlich M, Kuo KC. Quantitative reversed-phase high-performance liquid chromatography of major and modified nucleosides in DNA. J Chromatogr 1984;301:199-219.
16. Keuzenkamp-Jansen CW, De Abreu RA, Bökkerink JPM, Lambooy MAH, Trijbels JMF. Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-Hodgkin lymphoma. Am J Pediatr Hematol Oncol 1996;18:145-50.
17. Matsushima Y, Onodera H, Nagaoki T, Mitsumori K, Lu J, Maekawa A. Promoting effects of 6-mercaptopurine on carcinogenesis in various organs of F344 rats. Cancer Lett 1992;66: 147-53.